Halozyme Therapeutics, a biotechnology company developing novel oncology and drug-delivery therapies, announced it will expand and open a satellite office in San Francisco.
Halozyme is headquartered in San Diego and currently has about 200 employees. The new location will be on Gateway Boulevard in South San Francisco.
“The Bay Area satellite location will give us the ability to augment our already strong San Diego work force,” said Helen Torley, president and CEO of Halozyme, in a release.
According to Torley, the new location will help the company attract new talent, expand clinical programs and commercialize its new drug, PEGPH20. PEGPH20 is an investigational drug that targets solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor.